PARP1 and serum lipopolysaccharide activity: Our data, together with other published results, provide the ground for further studies of the underlying molecular mechanisms of cytoprotective and anti-inflammatory effects of PARP inhibitors, as well as the therapeutic potential of PARP inhibition to prevent or delay immune inflammatory diseases, including ovarian dysfunction, caused by endotoxemia.